Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Date:7/14/2008

>

Notes payable, less current portion - 119,000

Capital lease obligation, less current portion 22,000 30,000

Deferred license revenue - 4,000

Commitments and contingencies

STOCKHOLDERS' EQUITY:

Preferred stock - $.001 par value; authorized

5,000,000 shares; non-voting; nil shares

outstanding - -

Common stock - $.001 par value; authorized

325,000,000 shares; outstanding - 226,210,617

and 196,112,201, respectively 226,000 196,000

Additional paid-in-capital 246,205,000 224,453,000

Accumulated deficit (230,836,000) (207,660,000)

Total stockholders' equity 15,595,000 16,989,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $23,057,000 $22,997,000

-continued-

PEREGRINE PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2008

2008 2007 2006

REVENUES:

Contract manufacturing

revenue $5,897,000 $3,492,000 $3,005,000

License revenue 196,000 216,000 188,000

Total revenues 6,093,000 3,708,000 3,193,000

COSTS AND EXPENSES:

Cost of contract

manufacturing 4,804,000 3,296,000 3,297,000

Research and development 18,279,000 15,876,000 12,415,000

Selling, general and

administrative 7,150,000 6,446,000 6,564,000

Total costs and

expenses 30,233,000 25,618,000 22,276,000

LOSS FROM OPERATIONS (24,140,000) (21,910,000) (19,08
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of ... the quarter ended June 30, 2015, corporate highlights, ... management report are available at www.sedar.com ,  ... "RepliCel expects to launch its ...
(Date:8/27/2015)... VA (PRWEB) , ... August 27, 2015 , ... ... contractors solve complex business problems, is pleased to announce their ranking as one of ... annual ranking of the fastest-growing private companies across the nation. , “It is truly ...
(Date:8/27/2015)... , Aug. 27, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that executives ... in the month of September.  , ... at Rodman & Renshaw,s 17th Annual Global Investment Conference ... at the St. Regis Hotel in New ...
(Date:8/27/2015)... ... , ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately ... for the three years through 2014. Being named to the Inc. 5000 list designates ... country. , “We are thrilled to make the Inc. 5000 list for 2015,” ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... precisely how fluid boils in tiny "microchannels" has led ... systems to cool high-power electronics in electric and hybrid ... liquid to boil in cooling systems dramatically increases how ... a liquid to below its boiling point, said Suresh ...
... , SAN DIEGO, Sept. 22 SoluLinK, ... the TurboLink Conjugation Catalyst, making conjugation at least 20 times ... peptides and proteins. , , Up to ... conjugation speed for poor yields, poor quality and more labor ...
... , NEW YORK, Sept. 22 ... is available in its catalogue. , , ... and Wireless Systems, Data Processing, EMR Data Transfer) ... , , This report, High-Tech Patient ...
Cached Biology Technology:New findings could help hybrid, electric cars keep their cool 2New findings could help hybrid, electric cars keep their cool 3New findings could help hybrid, electric cars keep their cool 4SoluLinK Introduces Product that Links All Biomolecules Greater Than 20 Times Faster with 100% Yields 2Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 2Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 3Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 4Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 5Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 6Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 7Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 8Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 9Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 10
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
(Date:7/31/2015)... 2015 La 10 th International Conference on ... BGI del 22 al 25 de octubre de 2015 en ... la conferencia celebra su décimo aniversario. Desde su inauguración en ... las reuniones anuales más influyentes del mundo en el campo ... entusiastas y mejores a nivel científico. ICG-10 ...
(Date:7/31/2015)... -- The 10 th International Conference on Genomics (ICG-10, ... 2015, in Shenzhen , China ... th anniversary this year. Since its inauguration in 2006, ... meetings in the ,omics, fields, and is one of the ... ICG-10 focuses on recent breakthroughs and advances in ,omics, research ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... A. Wells, professor and chairman of the department pharmaceutical ... director of UCSF,s small molecule discovery center, has been ... Biochemistry and Molecular Biology-Merck Award for his pioneering studies ... who also serves on the ASBMB Council, will present ...
... technological innovation with business collaboration to improve conditions for ... new Hunter and Stephanie Hunt Institute for Engineering and ... Gifts totaling $5 million from Hunter and ... B. Lyle and others will establish the institute and ...
... Scientists have designed a synthetic protein that is ... of a native protein, nitric-oxide reductase. , The ... studying nitric-oxide reductase, and for creating biocatalysts for ... Illinois chemistry professor Yi Lu, who directed the ...
Cached Biology News:University of California, San Francisco, researcher receives ASBMB-Merck Award 2New engineering institute to modify, develop technology for the global poor 2New engineering institute to modify, develop technology for the global poor 3Synthetic protein mimics structure, function of metalloprotein in nature 2
solute carrier family 25, member 13 (citrin)...
poliovirus receptor-related 2 (herpesvirus entry mediator B), mRNA...
CREB-2 (H-290)...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Biology Products: